[{"NetIncomeLoss_1_Q1_USD":-23998000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-33000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0_Q1_USD":66300000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q1_USD":42700000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1_Q1_pure":0.0097,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":-6793000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1_Q1_shares":1158840.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q1_USD":-33000.0,"AssetsCurrent_0_Q1_USD":285508000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_1_Q1_USD":87205000.0,"DefinedContributionPlanAdministrativeExpenses_1_Q1_USD":200000.0,"DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_1_Q1_pure":0.5,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0_Q1_USD":14.27,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":9023822.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q1_USD":1316000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1_Q1_USD":80552000.0,"CommonStockSharesIssued_0_Q1_shares":43939246.0,"IncreaseDecreaseInAccountsReceivableRelatedParties_1_Q1_USD":1570000.0,"Assets_0_Q1_USD":298072000.0,"ShareBasedCompensation_1_Q1_USD":2660000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":4653000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1_Q1_USD":14.08,"OtherAccountsPayableAndAccruedLiabilities_0_Q1_USD":17680000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.0,"DueToRelatedPartiesCurrent_0_Q1_USD":6823000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_1_Q1_pure":0.902,"AccruedLiabilitiesCurrent_0_Q1_USD":17680000.0,"CommitmentsAndContingencies_0_Q1_USD":null,"ResearchAndDevelopmentExpense_1_Q1_USD":24245000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0_Q1_USD":14.27,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1_Q1_USD":-23000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":-79000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":0.0,"CommonStockValue_0_Q1_USD":null,"DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_1_Q1_USD":58000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":180000.0,"EffectiveIncomeTaxRateContinuingOperations_1_Q1_pure":-0.009,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":979000.0,"PaymentsOfStockIssuanceCosts_1_Q1_USD":148000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-24059000.0,"AccruedEmployeeBenefitsCurrent_0_Q1_USD":1775000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":83000000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":4102000.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":567176000.0,"Liabilities_0_Q1_USD":38738000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1_Q1_USD":1316000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":-28000.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"MarketableSecuritiesCurrent_0_Q1_USD":190476000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0_Q1_USD":12.22,"GeneralAndAdministrativeExpense_1_Q1_USD":5965000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":44224169.0,"DueFromRelatedPartiesCurrent_0_Q1_USD":3996000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q1_USD":17.29,"IncreaseDecreaseInContractWithCustomerLiability_1_Q1_USD":-8709000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":-57000.0,"CommonStockSharesAuthorized_0_Q1_shares":90000000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q1_USD":-61000.0,"DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_1_Q1_USD":3500.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-23998000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":2660000.0,"IncreaseDecreaseInAccountsPayableRelatedParties_1_Q1_USD":4091000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-28756000.0,"MarketableSecuritiesNoncurrent_0_Q1_USD":6254000.0,"LiabilitiesCurrent_0_Q1_USD":34515000.0,"AccountsPayableCurrent_0_Q1_USD":2732000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":83225000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":6213000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0_Q1_shares":5698164.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1_Q1_pure":0.898,"EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1_Q1_pure":0.21,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0_Q1_USD":66300000.0,"CashEquivalentsAtCarryingValue_0_Q1_USD":79151000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1_Q1_pure":0.0011,"StockIssuedDuringPeriodSharesStockOptionsExercised_1_Q1_shares":94149.0,"NumberOfOperatingSegments_1_Q1_segment":1.0,"OperatingLeasePayments_1_Q1_USD":491000.0,"PreferredStockSharesIssued_0_Q1_shares":0.0,"CapitalExpendituresIncurredButNotYetPaid_1_Q1_USD":97000.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0_Q1_USD":37300000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":1432000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":398000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q1_USD":1100000.0,"RestrictedCashNoncurrent_0_Q1_USD":225000.0,"CommonStockSharesOutstanding_0_Q1_shares":43939246.0,"OperatingIncomeLoss_1_Q1_USD":-24021000.0,"IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_1_Q1_USD":-673000.0,"StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_1_Q1_shares":14647.0,"IncomeTaxesReceivable_0_Q1_USD":1823000.0,"IncreaseDecreaseInIncomeTaxesReceivable_1_Q1_USD":751000.0,"InvestmentIncomeInterest_1_Q1_USD":102000.0,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":5768000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1_Q1_USD":23.41,"PreferredStockValue_0_Q1_USD":null,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1_Q1_USD":8.46,"LiabilitiesAndStockholdersEquity_0_Q1_USD":298072000.0,"PreferredStockSharesAuthorized_0_Q1_shares":10000000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":2660000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":1512000.0,"OperatingExpenses_1_Q1_USD":30210000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.54,"ProfitLoss_1_Q1_USD":-23998000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":121000.0,"StockholdersEquity_0_Q1_USD":259334000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":140000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":-348000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q1_shares":5698164.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q1_shares":2730013.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-307809000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-34593000.0,"IncreaseDecreaseInAccountsPayableTrade_1_Q1_USD":-344000.0,"AccruedProfessionalFeesCurrent_0_Q1_USD":723000.0,"Ticker":"PTGX","CIK":"1377121","name":"PROTAGONIST THERAPEUTICS, INC","OfficialName":"Protagonist Therapeutics Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"939483174.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210504"}]